El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

cam4.1217.pdf (192.51 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2017-12-01

Llicència de publicació

cc by (c) Jiménez Ubieto et al., 2017
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/124034

Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1002/cam4.1217

Resum

Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier end points, proposed in the setting of first-line chemo-/immunotherapy, as surrogates for OSprogression-free survival (PFS) status at 24months (PFS24) and complete response at 30months (CR30) post-ASCT. We also have investigated the clinical features of patients with early progression after ASCT. Data were available for 626 chemosensitive FL patients who received ASCT between 1989 and 2007. Median follow-up was 12.2years from ASCT. In the PFS24 analysis, 153 (24%) patients progressed within 24months and 447 were alive and progression-free at 24months post-ASCT (26 who died without disease progressions within 24months were excluded). Early progression was associated with shorter OS (hazard ratio [HR], 6.8; P=0.00001). In the subgroup of patients who received an ASCT in the setting or relapse after being exposed to rituximab, the HR was 11.3 (95% CI, 3.9-30.2; P<0.00001). In the CR30 analysis, 183 of 596 (31%) response-evaluable patients progressed/died with 30months post-ASCT. The absence of CR30 was associated with shorter OS (HR, 7.8; P<0.00001), including in patients with prior rituximab (HR, 8.2). PFS24 and CR30 post-ASCT are associated with poor outcomes and should be primary end points. Further research is needed to identify this population to be offered alternative treatments.

Matèries

Limfomes, Cèl·lules mare

Matèries (anglès)

Lymphomas, Stem cells

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

JIMÉNEZ UBIETO, Ana, GRANDE, Carlos, CABALLERO, Dolores, YÁÑEZ, Lucrecia, NOVELLI, Silvana, HERNÁNDEZ, Miguel t., MANZANARES, María, ARRANZ, Reyes, FERREIRO, José javier, BOBILLO, Sabela, MERCADAL, Santiago, GALEGO, Andrea, LÓPEZ JIMÉNEZ, Javier, MORALEDA, José maría, VALLEJO, Carlos, ALBO, Carmen, PÉREZ, Elena, MARRERO, Carmen, MAGNANO, Laura, PALOMERA, Luis, JARQUE, Isidro, CORIA, Erika, RODRIGUEZ, Antonia, MARTÍN, Alejandro, LÓPEZ GUILLERMO, Armando, SALAR, Antonio, LAHUERTA, Juan josé, GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea). Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma. _Cancer Medicine_. 2017. Vol. 6, núm. 12, pàgs. 2766-2774. [consulta: 8 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/124034]

Exportar metadades

JSON - METS

Compartir registre